Composition for preventing, improving or treating benign prostatic hyperplasia containing corilagin as an active ingredient

Corilagin compositions address the limitations of existing BPH treatments by safely reducing prostate size and weight through apoptosis regulation, providing enhanced efficacy in combination therapies.

KR1020260164458APending Publication Date: 2026-11-17UNIVERSITY INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020260038118
Authority / Receiving Office
KR · KR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-03-03
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing treatments for benign prostatic hyperplasia (BPH) are either temporary, have side effects, or require long periods to show effects, necessitating the development of a safe and effective natural ingredient.

Method used

A pharmaceutical and food composition containing corilagin, a natural polyphenol compound, which reduces prostate size, weight, and epithelial tissue thickness by regulating apoptosis-related proteins and the Notch signaling pathway, and can be used in combination with existing treatments.

Benefits of technology

Corilagin effectively inhibits prostate enlargement with no toxicity to normal cells, offering superior therapeutic effects when combined with conventional treatments, reducing prostate size, weight, and epithelial tissue thickness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PAT00004_ABST
    Figure PAT00004_ABST
Patent Text Reader

Abstract

The present invention relates to a composition for the prevention, improvement, or treatment of benign prostatic hyperplasia comprising corilagin as an active ingredient. The composition for the prevention, improvement, or treatment of benign prostatic hyperplasia comprising corilagin as an active ingredient according to the present invention exhibits excellent effects in reducing prostate size, prostate weight, and prostate epithelial tissue thickness. Furthermore, it can effectively suppress benign prostatic hyperplasia by promoting p53-mediated apoptosis and regulating the Notch1 / Hes1 / PTEN signaling pathway. In addition, it exhibits excellent safety as it has no toxicity to normal prostate cells and shows excellent synergistic effects when used in combination with existing therapeutic agents. Therefore, corilagin according to the present invention can be usefully utilized as a pharmaceutical composition, food composition, or health functional food composition for the prevention, improvement, or treatment of benign prostatic hyperplasia.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a composition for the prevention, improvement, or treatment of benign prostatic hyperplasia comprising chorillazine as an active ingredient. Background Technology

[0003] The prostate is the primary male gonad involved in male fertility, related to sperm activation and receptivity, and serves as a direct target for benign and malignant diseases such as prostatitis, benign prostatic hyperplasia, and prostate cancer. The incidence of urological diseases increases in middle-aged men, and the prevalence rises with age.

[0004] Benign prostatic hyperplasia (BPH) is a condition in which an enlarged prostate compresses the urethra, causing lower urinary tract symptoms such as frequent urination, urinary incontinence, urgency, and delayed urination. The primary precipitating factors for BPH are increasing age and male hormones; histological enlargement of the prostate begins at age 35, appearing in 60% of men in their 60s and 90% of men in their 80s, with 50% of these patients complaining of urinary dysfunction due to the enlargement. Male hormones in the prostate are deeply involved in the growth, development, and pathological state of the prostate through male hormone receptors. In particular, type 2 5-alpha reductase present in the prostate plays a crucial role in the development of BPH by converting male hormones into dihydrotestosterone (DHT), a more potent male hormone.

[0005] Drug treatments for benign prostatic hyperplasia (BPH) primarily consist of selective alpha-blockers and 5-alpha-reductase inhibitors (androgen inhibitors). Alpha-blockers are medications that reduce pressure and tension in the prostatic urethra; commercially available alpha-blockers include terazosin, doxazosin, tamsulosin, and alfuzosin. However, alpha-blockers are only a temporary treatment as they do not reduce the enlargement of the prostate, and side effects such as dizziness, lethargy, headache, and visual disturbances have been reported. 5-alpha-reductase inhibitors are drugs that prevent prostate enlargement by inhibiting 5-alpha-reductase, which plays a key role in the process of prostate enlargement. Finasteride and dutasteride are commercially available 5-alpha-reductase inhibitors. However, these drugs take a long time to show effects after taking them and have side effects related to sexual function.

[0006] Meanwhile, combination therapies employing drugs with different mechanisms of action are being attempted to enhance the therapeutic effect of benign prostatic hyperplasia. However, as previously mentioned, existing treatments exhibit various side effects; therefore, there is a need for the development of natural ingredients that offer high safety and superior efficacy when administered in combination.

[0007] Accordingly, the inventors of the present invention sought to develop a treatment for benign prostatic hyperplasia that is effective, safe, and free from side effects, and completed the present invention by confirming that Corilagin is effective in treating benign prostatic hyperplasia. Prior art literature

[0009] Korean Registered Patent No. 10-2757374 The problem to be solved

[0010] The object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia comprising corilagin, a pharmaceutically acceptable salt thereof, or a hydrate thereof as an active ingredient.

[0011] In addition, another objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia comprising corilagin, a pharmaceutically acceptable salt or hydrate thereof, and a treatment for benign prostatic hyperplasia as active ingredients.

[0012] In addition, another object of the present invention is to provide a method for treating a pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia comprising corilagin, a pharmaceutically acceptable salt thereof, or a hydrate thereof as an active ingredient.

[0013] In addition, another object of the present invention is to provide a method for treating a pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia comprising corilagin, a pharmaceutically acceptable salt or hydrate thereof, and a treatment for benign prostatic hyperplasia as active ingredients.

[0014] In addition, another objective of the present invention is to provide a food composition for the prevention or improvement of benign prostatic hyperplasia comprising corilagin, a food-grade salt thereof, or a hydrate thereof as an active ingredient.

[0015] In addition, another objective of the present invention is to provide a health functional food composition for improving prostate health comprising corilagin, a food-grade salt thereof, or a hydrate thereof as an active ingredient. means of solving the problem

[0017] To achieve the above objectives, the present invention provides a pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia comprising corilagin, a pharmaceutically acceptable salt thereof, or a hydrate thereof as an active ingredient.

[0018] The above-mentioned corilagin may be represented by Chemical Formula 1.

[0019] The above composition may reduce the size of the prostate.

[0020] The above composition may reduce the weight of the prostate.

[0021] The above composition may reduce the thickness of the prostate epithelial tissue.

[0022] The above composition may reduce the expression of the anti-apoptotic factor Bcl-2 or Bcl-xL.

[0023] The above composition may increase the expression of Bax, a pro-apoptotic factor.

[0024] The above composition may increase the expression of the tumor suppressor protein p53.

[0025] The above composition may reduce the expression of Notch1.

[0026] The above composition may reduce the expression of Hes1.

[0027] The above composition may increase the expression of PTEN, a tumor suppressor protein.

[0028] The above-mentioned corilagin may be included at a concentration of less than 10 mg / kg.

[0029] The above composition may not be toxic to normal prostate epithelial cells.

[0030] The above-mentioned corilagin may be included at a concentration of less than 100 μM.

[0031] The above normal prostate epithelial cells may be RWPE-1 cells.

[0032] The above composition may inhibit the proliferation of hypertrophic prostate epithelial cells.

[0033] The above-mentioned prostate enlargement epithelial cells may be BPH-1 cells.

[0034] In addition, the present invention provides a method for treating benign prostatic hyperplasia comprising the step of administering a pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia, comprising corilagin, a pharmaceutically acceptable salt thereof, or a hydrate thereof, as an active ingredient, to an individual other than a human who has developed or is at risk of developing benign prostatic hyperplasia.

[0035] In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia comprising corilagin, a pharmaceutically acceptable salt or hydrate thereof, and a treatment for benign prostatic hyperplasia as active ingredients.

[0036] The above-mentioned treatment for benign prostatic hyperplasia may be finasteride.

[0037] The above composition may exhibit a superior inhibitory effect on the proliferation of prostate enlargement cells in combination treatment compared to treatment with corilagin alone or treatment with finasteride alone.

[0038] In addition, the present invention provides a method for treating benign prostatic hyperplasia comprising the step of administering a pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia, comprising corilagin, a pharmaceutically acceptable salt or hydrate thereof, and a treatment for benign prostatic hyperplasia as active ingredients, to an individual other than a human who has developed or is at risk of developing benign prostatic hyperplasia.

[0039] In addition, the present invention provides a food composition for the prevention or improvement of benign prostatic hyperplasia comprising corilagin, a food-grade salt thereof, or a hydrate thereof as an active ingredient.

[0040] In addition, the present invention provides a health functional food composition for improving prostate health comprising corilagin, a food-grade salt thereof, or a hydrate thereof as an active ingredient.

[0041] The above-mentioned improvement of prostate health may involve maintaining prostate health by preventing or improving benign prostatic hyperplasia. Effects of the invention

[0043] A composition for the prevention, improvement, or treatment of benign prostatic hyperplasia comprising corilagin according to the present invention has excellent effects of reducing prostate size, prostate weight, and prostate epithelial tissue thickness. Therefore, corilagin according to the present invention can be usefully utilized as a pharmaceutical composition, food composition, or health functional food composition for the prevention, improvement, or treatment of benign prostatic hyperplasia.

[0044] Furthermore, the composition containing corilagin as an active ingredient according to the present invention can effectively inhibit prostate enlargement by regulating apoptosis-related proteins and the Notch signaling pathway, and exhibits excellent safety as it has no toxicity to normal prostate epithelial cells. Moreover, when the composition is used in combination with existing treatments for benign prostatic hyperplasia, it exhibits a superior therapeutic effect compared to treatment alone. Brief explanation of the drawing

[0046] Figure 1 is a figure showing the results of confirming the effect of reducing prostate size following the administration of Corilagin in an animal model of prostate enlargement in one embodiment of the present invention. FIG. 2 is a figure showing the results of confirming the effect of reducing prostate weight following the administration of Corilagin in an animal model of benign prostatic hyperplasia in one embodiment of the present invention (###p < 0.001 vs. Con group; **p < 0.01, ***p < 0.001 vs. BPH group). FIG. 3 is a figure showing the results of confirming the effect of reducing prostate weight per body weight following the administration of Corilagin in an animal model of benign prostatic hyperplasia in one embodiment of the present invention (###p < 0.001 vs. Con group; *p < 0.05 vs. BPH group). FIG. 4 is a figure showing the results of confirming the effect of relative prostate weight reduction following the administration of Corilagin in an animal model of benign prostatic hyperplasia in one embodiment of the present invention (###p < 0.001 vs. Con group; **p < 0.01, ***p < 0.001 vs. BPH group). FIG. 5 is a figure showing the results of confirming the effect of reducing prostate epithelial tissue thickness following the administration of Corilagin in an animal model of benign prostatic hyperplasia in one embodiment of the present invention (###p < 0.001 vs. Con group; ***p < 0.001 vs. BPH group). FIG. 6 is a figure showing the results of confirming the effect of corilagin administration on the expression of p53-mediated apoptosis-related proteins in an animal model of benign prostatic hyperplasia in one embodiment of the present invention (###p < 0.001 vs. Con group; ***p < 0.001 vs. BPH group). FIG. 7 is a figure showing the results of confirming the effect of corilagin administration on the expression regulation of Notch1, Hes1, and PTEN proteins in an animal model of benign prostatic hyperplasia in one embodiment of the present invention (###p < 0.001 vs. Con group; ***p < 0.001 vs. BPH group). FIG. 8 is a figure showing the results of confirming the inhibitory effect on the proliferation of enlarged prostate cell lines by combined treatment with corilagin and a conventional therapeutic agent in one embodiment of the present invention (*p < 0.05, **p < 0.01, ***p < 0.001 vs. Vehicle (DMSO) treatment group). Specific details for implementing the invention

[0047] Hereinafter, the present invention will be described in detail with reference to the attached drawings for embodiments of the present invention. However, the following embodiments are presented as examples of the present invention, and if it is determined that a detailed description of a technology or configuration well known to those skilled in the art may unnecessarily obscure the essence of the present invention, such detailed description may be omitted, and the present invention is not limited by this. The present invention is capable of various modifications and applications within the scope of the claims set forth below and the equivalent scope interpreted therefrom.

[0048] Furthermore, the terminology used in this specification is used to appropriately describe preferred embodiments of the present invention, and may vary depending on the intent of the user or operator, or the conventions of the field to which the present invention belongs. Accordingly, the definitions of these terms should be based on the content throughout this specification. Throughout the specification, when a part is described as "comprising" a certain component, unless specifically stated otherwise, this means that it does not exclude other components but may include additional components.

[0049] Throughout this specification, '%' used to indicate the concentration of a particular substance is (w / w) % for solid / solid, (w / v) % for solid / liquid, and (v / v) % for liquid / liquid, unless otherwise noted.

[0051] In one aspect, the present invention provides a pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia comprising corilagin, a pharmaceutically acceptable salt thereof, or a hydrate thereof as an active ingredient.

[0052] The term "Corilagin" used in this invention refers to coral saplings (Guatemalan rhubarb) ( Jatropha podagrica It is a natural polyphenol compound of the ellagitannin family isolated from the stems and roots of ), with the molecular formula C 27 H 22 O 18 and the IUPAC name is [(1 S ,19 R ,21 S ,22 R ,23 R )-6,7,8,11,12,13,22,23-octahydroxy-3,16-dioxo-2,17,20-trioxatetracyclo[17.3.1.0 4,9 .0 10,15 ]tricosa-4,6,8,10,12,14-hexaen-21-yl] 3,4,5-trihydroxybenzoate, and has a molecular weight of 634.5 g / mol.

[0053] In one embodiment of the present invention, the corilagin may be represented by the following chemical formula 1, but is not limited thereto.

[0054] [Chemical Formula 1]

[0055]

[0056] In one embodiment of the present invention, the composition may reduce the size of the prostate, but is not limited thereto.

[0057] In one embodiment of the present invention, the composition may reduce the weight of the prostate, but is not limited thereto.

[0058] In one embodiment of the present invention, the composition may reduce the thickness of the prostate epithelial tissue, but is not limited thereto.

[0059] In one embodiment of the present invention, the composition may reduce the expression of the anti-apoptotic factor Bcl-2 (B-cell lymphoma 2) or Bcl-xL (B-cell lymphoma-extra large), but is not limited thereto.

[0060] In one embodiment of the present invention, the composition may increase the expression of the apoptotic factor Bax (Bcl-2-associated X protein), but is not limited thereto.

[0061] In one embodiment of the present invention, the composition may increase the expression of the tumor suppressor protein p53, but is not limited thereto.

[0062] In one embodiment of the present invention, the composition may reduce the expression of Notch1 (Notch homolog 1), but is not limited thereto.

[0063] In one embodiment of the present invention, the composition may reduce the expression of Hes1 (Hairy and enhancer of split 1), but is not limited thereto.

[0064] In one embodiment of the present invention, the composition may increase the expression of PTEN (Phosphatase and tensin homolog), a tumor suppressor protein, but is not limited thereto.

[0065] In one embodiment of the present invention, the corilagin may be included at a concentration of less than 10 mg / kg, but is not limited thereto.

[0066] In one embodiment of the present invention, the composition may inhibit the proliferation of hypertrophic prostate epithelial cells, but is not limited thereto.

[0067] In one embodiment of the present invention, the prostate enlargement epithelial cells may be BPH-1 cells, but are not limited thereto.

[0068] The term "prostate enlargement epithelial cells" as used in the present invention refers to epithelial cells derived from a patient with prostate enlargement or a prostate enlargement model, and includes prostate enlargement epithelial cell lines.

[0069] In one embodiment of the present invention, the corilagin may be included at a concentration of less than 100 μM, preferably at a concentration of 1.5625 to 50 μM, but is not limited thereto.

[0070] In one embodiment of the present invention, the composition may be non-toxic to normal prostate epithelial cells, but is not limited thereto. Here, the normal prostate epithelial cells may be RWPE-1 cells, but are not limited thereto. Through this, the composition of the present invention can selectively inhibit enlarged prostate cells without affecting normal cells, thereby providing excellent safety.

[0072] The term "prevention" above refers to any act that reduces the frequency or severity of the occurrence of pathological phenomena. Prevention may be complete or partial. In this case, it may refer to a phenomenon in which symptoms of benign prostatic hyperplasia in an individual are reduced compared to the case where the composition is not used.

[0073] The above "treatment" refers to any act of clinical intervention intended to alter the natural processes of the target or cell to be treated, and may be performed during the progression of a clinical pathological condition or to prevent it. The intended therapeutic effects may include preventing the onset or recurrence of the disease, alleviating symptoms, reducing all direct or indirect pathological consequences associated with the disease, preventing metastasis, slowing the rate of disease progression, alleviating or temporarily resolving the disease state, or improving the prognosis.

[0074] The pharmaceutical composition of the present invention may additionally include an adjuvant in addition to corilagin. Any adjuvant known in the art may be used without limitation, but, for example, a complete or incomplete adjuvant of Freund may be additionally included to increase immunity.

[0075] The pharmaceutical composition according to the present invention may be prepared in the form of incorporating corilagin into a pharmaceutically acceptable carrier. Here, the pharmaceutically acceptable carrier includes carriers, excipients, and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers that can be used in the pharmaceutical composition of the present invention are not limited to these, but may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.

[0076] The pharmaceutical composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, external formulations, suppositories, or sterile injectable solutions, each according to conventional methods.

[0077] When formulating, it may be prepared using diluents or excipients such as commonly used fillers, volume expanders, binders, wetting agents, disintegrants, and surfactants. Solid dosage forms for oral administration include tablets, pills, powders, granules, and capsules, and such solid dosage forms may be prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc., with corilagin. In addition, lubricants such as magnesium stearate and talc may also be used in addition to simple excipients. Liquid dosage forms for oral administration include suspensions, liquids, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, flavoring agents, and preservatives, in addition to commonly used diluents such as water and liquid paraffin. Preparations for parenteral administration include sterile aqueous solutions, water-insoluble solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Water-insoluble solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Bases for suppositories may include Witepsol, Tween 61, cocoa paste, laurin paste, glycerogelatin, etc.

[0078] The pharmaceutical composition according to the present invention may be administered to an individual by various routes. Any mode of administration may be anticipated, for example, by oral, intravenous, intramuscular, subcutaneous, or intraperitoneal injection.

[0079] The dosage of the pharmaceutical composition according to the present invention is selected by taking into consideration the age, weight, gender, physical condition, etc. of the individual. It is obvious that the concentration of corilagin included in the pharmaceutical composition can be selected in various ways depending on the subject, and preferably, it is included in the pharmaceutical composition at a concentration of 0.01 to 5,000 μg / ml. If the concentration is less than 0.01 μg / ml, pharmaceutical activity may not appear, and if it exceeds 5,000 μg / ml, it may exhibit toxicity to the human body.

[0080] The above pharmaceutical composition can be formulated into various oral or parenteral administration forms.

[0081] Oral dosage forms include, for example, tablets, pills, hard and soft capsules, liquids, suspensions, emulsifiers, syrups, granules, etc., and these dosage forms may additionally contain diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine) and lubricants (e.g., silica, talc, stearic acid and its magnesium or calcium salts and / or polyethylene glycol) in addition to corilagin. Furthermore, the tablets may contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidine, and in some cases may contain disintegrants or boiling mixtures such as starch, agar, alginic acid or its sodium salt and / or absorbents, coloring agents, flavoring agents and sweeteners. The above formulation can be prepared by conventional mixing, granulation, or coating methods.

[0082] In addition, representative formulations for parenteral administration are injectable preparations, and solvents for injectable preparations include water, Ringer's solution, isotonic saline, or suspensions. The sterile fixation oil of the above injectable preparation can be used as a solvent or suspension medium, and any non-irritating fixation oil, including mono- and di-glycerides, can be used for this purpose.

[0083] In addition, the above-mentioned injectable formulation may use fatty acids such as oleic acid.

[0085] In one aspect, the present invention provides a pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia comprising corilagin, a pharmaceutically acceptable salt or hydrate thereof, and a treatment for benign prostatic hyperplasia as active ingredients.

[0086] The term "treatment for benign prostatic hyperplasia" used in the present invention refers to a drug that alleviates the symptoms of benign prostatic hyperplasia or inhibits its progression, and includes, but is not limited to, 5-alpha-reductase inhibitors, alpha-blockers, phosphodiesterase-5 inhibitors, anti-androgens, etc.

[0087] In one embodiment of the present invention, the treatment for benign prostatic hyperplasia may be a 5-alpha-reductase inhibitor, but is not limited thereto.

[0088] The term "5-alpha-reductase inhibitor" used in the present invention refers to a drug that blocks the conversion of testosterone into dihydrotestosterone (DHT) by inhibiting the activity of 5-alpha-reductase.

[0089] In one embodiment of the present invention, the 5-alpha-reductase inhibitor may be finasteride or dutasteride, preferably finasteride, but is not limited thereto.

[0090] In one embodiment of the present invention, the treatment for benign prostatic hyperplasia may be an alpha-blocker, and the alpha-blocker may be terazosin, doxazosin, tamsulosin, alfuzosin, silodosin, etc., but is not limited thereto.

[0091] In one embodiment of the present invention, the composition may exhibit a superior inhibitory effect on the proliferation of prostate enlargement cells in combination treatment compared to treatment with corilagin alone or treatment with a prostate enlargement treatment agent alone, but is not limited thereto.

[0092] In one embodiment of the present invention, the composition may exhibit a superior inhibitory effect on the proliferation of prostate enlargement cells in combination treatment compared to treatment with corilagin alone or treatment with finasteride alone, but is not limited thereto.

[0093] In one embodiment of the present invention, the corilagin and the treatment for benign prostatic hyperplasia may be formulated as a single formulation or as separate formulations and administered simultaneously or sequentially, but are not limited thereto.

[0094] The above combination composition can be formulated in the same way as the pharmaceutical composition described above, and can follow the same administration route and method.

[0096] In one aspect, the present invention provides a composition for inhibiting the proliferation of epithelial cells of a hypertrophic prostate, comprising corilagin, a pharmaceutically acceptable salt thereof, or a hydrate thereof as an active ingredient.

[0097] The term "prostate enlargement epithelial cells" as used in the present invention refers to epithelial cells derived from a patient with prostate enlargement or a prostate enlargement model, and includes prostate enlargement epithelial cell lines.

[0098] In one embodiment of the present invention, the prostate enlargement epithelial cells may be BPH-1 cells, but are not limited thereto.

[0099] In one embodiment of the present invention, the composition may inhibit the proliferation of prostate enlargement cells induced by dihydrotestosterone (DHT), but is not limited thereto.

[0100] In one embodiment of the present invention, the composition may inhibit the proliferation of prostate cells induced or promoted by male hormones, but is not limited thereto.

[0101] In one embodiment of the present invention, the composition for inhibiting the proliferation of epithelial cells of prostate enlargement can be used as a pharmaceutical composition for the prevention or treatment of prostate enlargement, and can be formulated and administered in the same manner as the pharmaceutical composition described above.

[0102] In one embodiment of the present invention, the composition may be applied to other prostate diseases associated with the excessive proliferation of prostate cells, but is not limited thereto.

[0104] In one aspect, the present invention provides a food composition for the prevention or improvement of benign prostatic hyperplasia comprising corilagin, a food-grade salt thereof, or a hydrate thereof as an active ingredient.

[0105] The food composition of the present invention can be formulated into various forms, such as tablets, pills, granules, capsules, liquid preparations, and beverages, and added to food. There are no specific restrictions on the types of food. Examples of foods to which the corilagin of the present invention can be added include drinks, meat, sausages, bread, biscuits, rice cakes, chocolates, candies, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, alcoholic beverages, vitamin complexes, dairy products, and dairy processed products, and include both health foods and health functional foods in the conventional sense.

[0106] The health food and health functional food compositions containing corilagin according to the present invention may be added directly to food or used together with other foods or food ingredients, and may be used appropriately according to conventional methods. The amount of corilagin mixed may be appropriately determined according to the purpose of use (for prevention or improvement). Generally, the amount of the above composition in the health food and health functional food may be added in an amount of 0.1 to 90 parts by weight of the total food weight. However, in the case of long-term consumption for the purpose of maintaining health or regulating health, the above amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount greater than the above range.

[0107] The health food and health functional food compositions of the present invention contain the Corilagin of the present invention as an essential component in the indicated proportions, and there are no special restrictions on other components; they may contain various flavoring agents or natural carbohydrates as additional components, as in ordinary beverages. Examples of the natural carbohydrates described above include monosaccharides, e.g., glucose, fructose, etc.; disaccharides, e.g., maltose, sucrose, etc.; polysaccharides, e.g., dextrin, cyclodextrin, etc., and conventional sugars, and sugar alcohols such as xylitol, sorbitol, erythritol, etc. Natural flavoring agents other than those described above (taumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) may be advantageously used. The ratio of the above natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 12 g per 100g of the health functional food composition of the present invention.

[0108] In addition to the above, the health food and health functional food compositions containing corilagin of the present invention may contain various nutritional supplements, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Furthermore, the health food and health functional food compositions of the present invention may contain fruit pulp for the production of natural fruit juices, fruit juice beverages, and vegetable beverages.

[0109] These ingredients may be used independently or in combination. Although the proportion of these additives is not that important, it is generally selected in the range of 0.1 to about 20 parts by weight per 100 parts by weight of the health food and health functional food composition containing corilagin of the present invention.

[0111] In one aspect, the present invention provides a health functional food composition for improving prostate health comprising corilagin, a food-grade salt thereof, or a hydrate thereof as an active ingredient.

[0112] In one embodiment of the present invention, the improvement of prostate health may be to maintain prostate health by preventing or improving benign prostatic hyperplasia, but is not limited thereto.

[0113] The term "health functional food" as used in this invention is synonymous with "food for special health use (FosHU)," and refers to a food with high medical or therapeutic effects that is processed to efficiently exhibit bio-regulatory functions in addition to nutritional supply. Here, "function" refers to obtaining useful effects for health purposes, such as regulating nutrients or physiological actions regarding the structure and function of the human body. The health functional food of this invention can be manufactured by methods commonly used in the industry, and during such manufacturing, raw materials and ingredients commonly added in the industry may be added. Furthermore, the formulation of the health functional food can be manufactured without restriction as long as it is a formulation recognized as a food. The health functional food of this invention can be manufactured in various forms of formulations. Unlike general pharmaceuticals, it uses food as a raw material, offering the advantage of not causing side effects that may occur with long-term use of pharmaceuticals. Additionally, due to its excellent portability, the health functional food of this invention can be consumed as an adjuvant to enhance the effect of improving prostate health.

[0114] The aforementioned health functional food refers to a food that possesses active effects of maintaining or promoting health compared to general food, and health supplement food refers to a food intended for the purpose of supporting health. In some cases, the terms health functional food, health food, and health supplement food are used interchangeably.

[0115] Specifically, the above-mentioned health functional food is a food prepared by adding the composition of the present invention to food materials such as beverages, teas, spices, gum, and confectionery, or by encapsulating, powdering, or suspension, and means that consuming it brings about specific health effects. Unlike general medicines, it has the advantage of not having side effects that may occur when taking medicine for a long period of time because it is made from food.

[0116] The above-mentioned health functional food may additionally include a physiologically acceptable carrier, the type of carrier is not particularly limited, and any carrier commonly used in the relevant technical field may be used.

[0117] In addition, the above-mentioned health functional food may include additional ingredients that are commonly used in food to improve smell, taste, visual appearance, etc. For example, it may include vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, pantothenic acid, etc. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), and copper (Cu); and amino acids such as lysine, tryptophan, cysteine, and valine.

[0118] In addition, the above-mentioned health functional food may include food additives such as preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), disinfectants (bleaching powder and high-grade bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), etc.), coloring agents (tar dyes, etc.), colorants (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite), seasonings (MSG, monosodium glutamate, etc.), sweeteners (dulcin, cyclamate, saccharin, sodium, etc.), flavorings (vanillin, lactones, etc.), leavening agents (alum, potassium hydrogen tartrate, etc.), reinforcing agents, emulsifiers, thickeners (sizing agents), coating agents, gum bases, antifoaming agents, solvents, and improvers. The above additives can be selected according to the type of food and used in appropriate amounts.

[0119] As an example of a health functional food of the present invention, it may be used as a health beverage composition, in which case it may contain various flavoring agents or natural carbohydrates as additional ingredients, as in conventional beverages. The natural carbohydrates described above may be monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrin and cyclodextrin; and sugar alcohols such as xylitol, sorbitol, and erythritol. Sweeteners may include natural sweeteners such as thaumatin and stevia extract; and synthetic sweeteners such as saccharin and aspartame. The proportion of the natural carbohydrates may generally be about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g per 100 mL of the health beverage composition of the present invention.

[0120] In addition to the above, the health drink composition may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, or carbonating agents. Furthermore, it may contain fruit pulp for the production of natural fruit juices, fruit juice beverages, or vegetable beverages. These ingredients may be used independently or in combination. Although the proportion of these additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health drink composition of the present invention.

[0122] In one aspect, the present invention provides a method for treating benign prostatic hyperplasia comprising the step of administering the pharmaceutical composition to an individual other than a human who has developed or is at risk of developing benign prostatic hyperplasia.

[0123] The term "administration" in this invention means introducing a specific substance to an individual by an appropriate method.

[0124] The term "individual" in this invention refers to animals other than humans, such as rats, mice, and livestock, that have developed or may develop benign prostatic hyperplasia. More specifically, it may be non-human mammals such as primates, mice, rats, dogs, cats, horses, and cattle.

[0125] The pharmaceutical composition of the present invention may be administered in a therapeutically effective amount or a pharmaceutically effective amount.

[0126] In the present invention, the term "therapeutically effective amount" refers to a pharmaceutically acceptable amount of salt of a composition effective for preventing or treating a target disease, and the therapeutically effective amount of the composition of the present invention may vary depending on various factors, such as the method of administration, the target site, the patient's condition, etc. Therefore, when used in humans, the dosage should be determined as an appropriate amount by considering both safety and efficacy. It is also possible to estimate the amount used in humans from the effective amount determined through animal experiments. Such matters to be considered when determining the effective amount are described, for example, in Hardman and Limbird, eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. (2001), Pergamon Press; and EW Martin ed., Remington's Pharmaceutical Sciences, 18th ed. (1990), Mack Publishing Co.

[0127] In the present invention, the term "pharmaceuticalally effective amount" refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment and that does not cause side effects, and the effective dose level may be determined based on factors including the patient's health condition, type and severity of the disease, drug activity, sensitivity to the drug, method of administration, time of administration, route of administration and elimination rate, duration of treatment, drugs used in combination or concurrently, and other factors well known in the medical field.

[0128] The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. Taking all of the above-mentioned factors into consideration, it is important to administer an amount that obtains maximum effect with a minimum amount without side effects, and this can be easily determined by a person skilled in the art.

[0129] The composition of the present invention may be administered at a dose of 0.0001 to 100 mg / kg body weight per day based on solid content, more specifically at a dose of 0.001 to 100 mg / kg body weight. The above recommended dose may be administered once a day or divided into several doses.

[0130] In the method for preventing or treating benign prostatic hyperplasia according to the present invention, the route and method of administration for administering the composition are not particularly limited and may follow any route and method of administration as long as the composition containing the composition can reach the intended site. Specifically, the composition may be administered through various routes of oral or parenteral administration, and non-limiting examples of such routes of administration include administration through the mouth, rectum, local, intravenous, intraperitoneal, intramuscular, intra-arterial, transdermal, nasal, or inhalation.

[0132] As described above, specific embodiments of the present invention have been described in detail; however, those skilled in the art who understand the spirit of the present invention will be able to easily propose other inventions that are inferior or other embodiments included within the scope of the spirit of the present invention by adding, changing, or deleting other components within the same spirit. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive. The scope of the present invention is defined by the claims set forth below rather than by the detailed description above, and all modifications or variations derived from the meaning and scope of the claims and equivalent concepts should be interpreted as being included within the scope of the present invention.

[0134] <Example 1> Isolation and Purification of Corilagin

[0135] Dried coral flow ( Jatropha podagrica400 g of the stems and roots of ) were placed in 700 mL of 80% methanol and extracted using a reflux condenser at 70 °C for 12 hours, and the extraction process was repeated a total of 3 times. Afterward, the extract was filtered and concentrated to obtain 72 g of crude extract. The obtained crude extract (72 g) was suspended in distilled water (700 mL), and solvent fractionation was performed 3 times using n-hexane (700 mL), ethyl acetate (700 mL), and n-butanol solvent (700 mL), thereby obtaining an n-hexane fraction (20.6 g), an ethyl acetate fraction (10.4 g), and an n-butanol fraction (10.4 g). HP-20 column chromatography was performed to remove sugar residues from the n-butanol fraction (10.4 g), using distilled water (2 L), methanol (2 L), and acetone (2 L) sequentially as elution solvents to obtain the distilled water fraction (6.3 g), methanol fraction (3.9 g), and acetone fraction (0.1 g), respectively. Of these, the methanol fraction (3.9 g) was fractionated using medium pressure liquid chromatography (MPLC) and eluted with a mobile phase gradient solvent system (methanol:distilled water = 90:10 to 50:50) to obtain a total of 7 subfractions (A~G). Subsequently, fraction D (580 mg) was subjected to open column chromatography using a sephadex LH-20 column and eluted with 80% methanol to obtain subfractions (D1~D8). Finally, fraction D7 (15.8 mg) was subjected to semi-preparative high performance liquid chromatography (semi-preparative HPLC), and corilagin (3.4 mg) was separated and purified using a mobile phase isosolvent system (methanol:distilled water = 23:77). Corilagin is represented by the following chemical formula 1.

[0137] [Chemical Formula 1]

[0138]

[0140] <Experimental Example 1> Confirmation of the effect of Corilagin in alleviating prostate enlargement

[0141] To confirm the effect of Corilagin in alleviating prostate enlargement, the size of the prostate was analyzed.

[0142] Specifically, for 4 weeks excluding weekends, rats were subcutaneously injected with 10 mg / kg of testosterone propionate (TP) and orally administered the positive control drug finasteride 5 mg / kg (Fina) and the drug groups Corilagin 5 and 10 mg / kg (Corilagin 5 and Corilagin 10). Subsequently, prostate tissue was obtained by dislocating the cervical vertebrae of the anesthetized rats, weighed, and the size of the prostate was observed visually.

[0143] As shown in Figure 1, the prostate size in the BPH group, in which prostate enlargement was induced, increased significantly compared to the Con group. On the other hand, the prostate size in the Fina group and the Corilagin 5 and Corilagin 10 groups decreased compared to the BPH group.

[0144] Through this, it was confirmed that Corilagin has an effect in alleviating prostate enlargement.

[0146] <Experimental Example 2> Confirmation of the prostate weight reduction effect of Corilagin

[0147] 2-1. Comparison of prostate weight with Corilagin

[0148] To confirm the prostate weight-reducing effect of Corilagin, the prostate weight of each experimental group was measured and compared.

[0149] As shown in Figure 2, the BPH group, which induced prostate enlargement, had a significantly increased prostate weight compared to the Con group. On the other hand, the Fina group and the Corilagin 5 and Corilagin 10 groups had a decreased prostate weight compared to the BPH group.

[0151] 2-2. Comparison of Prostate Weight Per Body Weight with Corilagin

[0152] To confirm the prostate weight-reducing effect of Corilagin, the change in prostate weight per body weight of each experimental group was measured.

[0153] As shown in Figure 3, the BPH group with induced prostate enlargement showed a significantly increased prostate weight per body weight compared to the Con group, but this was significantly reduced in the Fina group, Corilagin 5, and Corilagin 10 groups.

[0155] 2-3. Comparison of Relative Prostate Weight of Corilagin

[0156] To confirm the prostate weight reduction effect of Corilagin, the relative prostate weight ratio of each experimental group was measured.

[0157] As shown in Figure 4, the relative prostate weight ratio in the BPH group, which induced prostate enlargement, significantly increased compared to the Con group. On the other hand, the relative prostate weight ratio that increased in the Fina group, Corilagin 5, and Corilagin 10 groups decreased.

[0158] Through this, it was confirmed that Corilagin has the effect of reducing prostate weight.

[0160] <Experimental Example 3> Confirmation of the effect of Corilagin in reducing prostate epithelial tissue thickness

[0161] To confirm the effect of Corilagin on reducing the thickness of prostate epithelial tissue, prostate tissue sections were stained with hematoxylin & eosin (H&E) and the thickness of the prostate epithelial tissue was measured.

[0162] As shown in Figure 5, the prostate epithelial tissue thickness in the BPH group with induced prostate enlargement was significantly increased compared to the Con group, but was significantly decreased in the Fina group, Corilagin 5, and Corilagin 10 groups.

[0163] Through this, it was confirmed that Corilagin has an effect of reducing the thickness of prostate epithelial tissue.

[0165] <Experimental Example 4> Confirmation of the effect of Corilagin on p53-mediated apoptosis regulation

[0166] To investigate the effects of Corilagin on prostate overgrowth by regulating pathways associated with p53-mediated apoptosis, the expression of apoptosis-related factors was analyzed using prostate tissue isolated from an animal model of benign prostatic hyperplasia.

[0167] As shown in Figure 6, in the BPH group with induced prostate enlargement, the expression of anti-apoptotic factors Bcl-2 and Bcl-xL increased compared to the Con group, while the expression of pro-apoptotic factor Bax and tumor suppressor protein p53 decreased. Meanwhile, in the Corilagin 5 and Corilagin 10 groups, the expression of Bcl-2 and Bcl-xL decreased compared to the BPH group, and the expression of Bax and p53 significantly increased.

[0168] Through this, it was confirmed that Corilagin can influence the regulation of cell survival related to the development and progression of prostate enlargement by regulating the expression of proteins associated with the p53-mediated apoptosis pathway in an animal model of prostate enlargement induction.

[0170] <Experimental Example 5> Confirmation of the Modulating Effect of Corilagin on the Notch1 / Hes1 / PTEN Signaling Pathway

[0171] To determine whether Corilagin regulates the Notch signaling pathway associated with the development and progression of prostate enlargement, the expression of Notch1, Hes1, and PTEN proteins was analyzed using prostate tissue isolated from an animal model of prostate enlargement induction.

[0172] As shown in Figure 7, in the BPH group with induced prostate enlargement, the expression of Notch1 and Hes1 increased compared to the Con group, while the expression of the tumor suppressor protein PTEN decreased. On the other hand, in the Corilagin 5 and Corilagin 10 groups, the expression of Notch1 and Hes1 decreased compared to the BPH group, and the expression of PTEN significantly increased.

[0173] Through this, it was confirmed that Corilagin can be involved in regulating the abnormal proliferation of prostate tissue by inhibiting the activation of the Notch1 / Hes1 signaling pathway and restoring PTEN expression in an animal model of benign prostatic hyperplasia.

[0175] <Experimental Example 6> Confirmation of the inhibitory effect on the proliferation of benign prostatic hyperplasia cells by combined treatment with Corilagin and existing therapeutic agents

[0176] We confirmed whether Corilagin inhibits the proliferation of prostate enlargement cells and the effect of combination therapy with finasteride, an existing treatment for prostate enlargement.

[0177] First, normal prostate epithelial cell line RWPE-1 cells were treated with corilagin and finasteride at concentrations of 1.5625, 3.125, 6.25, 12.5, 25, 50, and 100 μM, respectively, and cell viability was measured.

[0178] As shown in Figure 8, no significant decrease in the viability of normal prostate epithelial cells was observed upon treatment with finasteride (Fina) within the above concentration range, and it was confirmed that cytotoxicity occurred upon treatment with corilagin, with a significant decrease in cell viability at a concentration of 100 μM.

[0179] Subsequently, Corilagin, Finasteride, and combination therapy groups were set up for BPH-1 cells, an epithelial cell line of prostate enlargement, and treated with 1.5625, 3.125, 6.25, 12.5, 25, and 50 μM, which are concentration ranges in which no toxicity was observed in the experiment.

[0180] As a result, treatment with Corilagin demonstrated an inhibitory effect on the proliferation of BPH-1 cells, with superior inhibitory effects confirmed particularly in the high-concentration treatment group. Furthermore, when Corilagin and finasteride were administered in combination, the proliferation of hypertrophic prostate epithelial cells was inhibited more effectively compared to the single-drug treatment groups.

[0181] Through this, it was confirmed that Corilagin can inhibit the proliferation of hypertrophic prostate epithelial cells against normal prostate epithelial cells within a non-toxic concentration range, and that the inhibitory effect on hypertrophic prostate cell proliferation can be enhanced through combination with existing treatments for hypertrophic prostate.

[0183] The present invention has been described above with reference to preferred embodiments and experimental examples. Those skilled in the art will understand that the present invention may be embodied in modified forms without departing from the essential characteristics of the invention. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the invention is defined by the claims, not by the foregoing description, and all variations within the scope of the claims should be interpreted as being included in the invention.

Claims

Claim 1 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia comprising corilagin, a pharmaceutically acceptable salt thereof, or a hydrate thereof as an active ingredient. Claim 2 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia according to claim 1, wherein the corilagin is represented by the following chemical formula 1: [Chemical Formula 1] . Claim 3 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia, wherein the composition reduces the size of the prostate. Claim 4 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia, wherein the composition reduces the weight of the prostate. Claim 5 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia, wherein the composition reduces the thickness of the prostate epithelial tissue in claim 1. Claim 6 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia according to claim 1, wherein the composition reduces the expression of anti-apoptotic factors Bcl-2 or Bcl-xL. Claim 7 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia, wherein the composition increases the expression of Bax, a pro-apoptotic factor, in claim 1. Claim 8 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia, wherein the composition increases the expression of the tumor suppressor protein p53, in accordance with claim 1. Claim 9 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia, wherein the composition reduces the expression of Notch1 in claim 1. Claim 10 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia, wherein the composition reduces the expression of Hes1 in claim 1. Claim 11 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia, wherein the composition increases the expression of PTEN, a tumor suppressor protein, in accordance with claim 1. Claim 12 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia according to claim 1, wherein the corilagin is contained at a concentration of less than 10 mg / kg. Claim 13 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia, wherein the composition is non-toxic to normal prostate epithelial cells. Claim 14 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia according to claim 13, wherein the above-mentioned corilagin is contained at a concentration of less than 100 μM. Claim 15 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia, wherein, in paragraph 13, the normal prostate epithelial cells are RWPE-1 cells. Claim 16 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia, wherein the composition inhibits the proliferation of hypertrophic prostatic epithelial cells. Claim 17 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia, wherein, in paragraph 16, the benign prostatic hyperplasia epithelial cells are BPH-1 cells. Claim 18 A method for treating benign prostatic hyperplasia comprising the step of administering the pharmaceutical composition of claim 1 to an individual other than a human who has developed or is at risk of developing benign prostatic hyperplasia. Claim 19 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia comprising corilagin, a pharmaceutically acceptable salt or hydrate thereof, and a treatment for benign prostatic hyperplasia as active ingredients. Claim 20 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia, wherein, in claim 19, the treatment for benign prostatic hyperplasia is finasteride. Claim 21 A pharmaceutical composition for the prevention or treatment of benign prostatic hyperplasia, wherein, in claim 20, the composition exhibits a superior inhibitory effect on the proliferation of benign prostatic hyperplasia cells in combination treatment compared to treatment with corilagin alone or treatment with finasteride alone. Claim 22 A method for treating benign prostatic hyperplasia comprising the step of administering the pharmaceutical composition of claim 19 to an individual other than a human who has developed or is at risk of developing benign prostatic hyperplasia. Claim 23 A food composition for the prevention or improvement of benign prostatic hyperplasia comprising corilagin, a food-grade salt thereof, or a hydrate thereof as an active ingredient. Claim 24 A health functional food composition for improving prostate health comprising corilagin, a food-grade salt thereof, or a hydrate thereof as an active ingredient. Claim 25 A health functional food composition for improving prostate health according to claim 24, wherein the improvement of prostate health is to maintain prostate health by preventing or improving benign prostatic hyperplasia.